

## DAFTAR PUSTAKA

- Al-droos, M. and Qubain, W., (2013). The Effect Of Intravitreal Avastin On Systemic Blood Pressure In Controlled Hypertensive Patients. *Med J Islam.* 21(2):77–80.
- Alahmari, A. K., Almalki, Z. S., Alahmari, A. K. and Guo, J. J., (2016) Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer. *Am Heal.* 9(4):221–232.
- Amadio, M., Govoni, S. and Pascale, A., (2016). Targeting VEGF in eye neovascularization: What's new? A comprehensive review on current therapies and oligonucleotide-based interventions under development. *Pharmacol Res.* 103:253–269.
- Avery, R. L., (2014). What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?. *Br J Ophthalmol.* 98:10–13.
- Avery, R. L. and Gordon, G. M., (2016). Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema A Systematic Review and Meta-analysis. *JAMA Ophthalmol.* 134(1):21–29.
- Bahrami, B., Zhu, M., Hong, T. and Chang, A., (2016). Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. *Diabetologia.* 59(8):1594–1608.
- Bakri, S. J., Snyder, M. R., Reid, J. M. and Pulido, J. S., (2007). Pharmacokinetics of Intravitreal Bevacizumab (Avastin). *Ophthalmology*, 114(5):855–859.
- Beevers, G., Lip, G. Y. H. and Brien, E. O., (2001). The pathophysiology of hypertension Cardiac output and peripheral resistance Renin-angiotensin system Autonomic nervous system. *BMJ.* 322:912–916.
- Bembde, A. S., (2012). A Study of Plasma Fibrinogen Level in Type-2 Diabetes Mellitus and its Relation to Glycemic Control. *Indian J Hematol Blood Transfus.* 28(2):105–108.
- Bom, J. G. Van Der, Maat, M. P. M. De, Bots, M. L., Haverkate, F., Jong, P. T. V. M. De, *et al.*, (1998). Elevated Plasma Fibrinogen Cause or Consequence of Cardiovascular Disease?. *Arter. Thromb Vasc Biol.* 18:621–625.
- Bracha, P., Moore, N. A., Ciulla, T. A., Wudunn, D. and Cantor, L. B., (2017). The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review. *Surv Ophthalmol.* 63:281–295.
- Bressler, S. B., Liu, D. and Wells, J. A., (2017). Change in Diabetic Retinopathy Through 2 Years. *JAMA Ophthalmol.* 135(6):558–568.

- Choi, H. M., Kim, H. C. and Kang, D. R., (2017). Sex differences in hypertension prevalence and control : Analysis of the 2010-2014 Korea National Health and Nutrition Examination Survey. *PLoS One*. 12(5):1-12.
- Costagliola, C., Agnifili, L., Arcidiacono, B., Duse, S., Fasanella, V., *et al.*, (2012). Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. *Expert Opin Biol Ther*. 12(10):1299-1313.
- Dhawale, S., Jayant, S. and Gupta, A. K., (2016). Serum fibrinogen level in type 2 diabetes mellitus patients. *Int J Adv Med*. 3(1):83-87.
- Eldour, A. A. A., Khalafallah, T. O., Noja, H. M., Saad, E. S. M., Elsayid, M., *et al.*, (2016). Fibrinogen Levels in Hypertensive and Normotensive : A Cross-Sectional Study. *J. Biosci. Med*. 4:28-32.
- Emanuele, N. V., Azad, N. E., Abraira, C. D., Henderson, W. G., Colwell, J. A., *et al.*, (1998). Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins. *Arch Intern Med*. 158:2485-2490.
- Falavarjani, K. G. and Nguyen, Q. D., (2013). Adverse events and complications associated with intravitreal injection of anti-VEGF agents : a review of literature. *Eye*. 27(7):787-794.
- Fiebai, B. and Odogu, V., (2017). Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases : An Audit. *Open Ophthalmol J*. 11:315-321.
- Garc, L., Luaces-rodr, A., Mondelo-garc, C., Maroñas, O., Mangas-sanjuan, V., *et al.*, (2019). Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. *Pharmaceutics*. 11(365):1-22.
- Ip, M. S., Scott, I. U., Brown, G. C., Brown, M. M., Huang, S. S., *et al.*, (2008). Anti-Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. *Ophthalmology*. 115(10):1837-1846.
- Jager, R. D., Aiello, L. P., Patel, S. C. and Cunningham, E. T., (2004). Risks of intravitreal injection: a comprehensive review. *Retina*. 24(5):676-698.
- Kaufman, C., Kinney, T. and Quencer, K., (2018). Practice Trends of Fibrinogen Monitoring in Thrombolysis. *J. Clin. Med*. 7(111):1-10.
- Lee, R., Wong, T. Y. and Sabanayagam, C., (2015). Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis*. 2(1):17.
- Lominadze, D., Dean, W. L., Tyagi, S. C. and Roberts, A. M., (2010). Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. *Acta Physiol*. 198(1):1-13.
- Lowe, G. D. O., Rumley, A. and Mackie, I. J., (2004). Plasma fibrinogen. *Ann Clin Biochem*. 41:430-440.

- Mahendra, J. V, D, S. K., Anuradha, T. S., Talikoti, P., Nagaraj, R. S., *et al.*, (2015). Plasma Fibrinogen in Type 2 Diabetic Patients with Metabolic Syndrome and its Relation with Ischemic Heart Disease (IHD) and Retinopathy. *J Clin Diagn Res.* 9(1):18–21.
- Majeed, A., Rashid, A., Maqbool, R., Rashid, W., Ahmed, M., *et al.*, (2016). Serum Fibrinogen Levels and its Relation to Hypertension. *Int J Sci Stud.* 3(8):72–75.
- Naz, A., Najam, R., Riaz, B. and Ahmed, A., (2014). Evaluation Of Intravitreal Bevacizumab For Its Systemic Side Effect Thrombosis After Chronic Administration. *J App Pharm.* 6(2):202–209.
- Papadakis, J. A., Ganotakis, E. S., Jagroop, I. A., Mikhailidis, D. P. and Winder, A. F., (1999). Effect of Hypertension and its Treatment on Lipid, Lipoprotein(a), Fibrinogen, and Bilirubin Levels in Patients Referred for Dyslipidemia. *AJH.* 12(7):673–681.
- Pourmoghdas, A., Gharipour, M., Garakyaraghi, M., Nouri, F. and Sadeghi, M., (2018). Association of socioeconomic status and hypertension based on habitual smoking among Iranian population : IHHP study. *Acta Biomed.* 89(4):498–504.
- Pożarowska, D. and Pożarowski, P., (2016). The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. *Cent Eur J Immunol.* 41(3):311–316.
- Previtali, E., Bucciarelli, P., Passamonti, S. M. and Martinelli, I., (2011). Risk factors for venous and arterial thrombosis. *Blood Transfus.* 9(2):120–138.
- Risimic, D., Milenkovic, S., Nikolic, D., Simeunovic, D., Jaksic, V., *et al.*, (2013). Influence of Intravitreal Injection of Bevacizumab on Systemic Blood Pressure Changes in Patients with Exudative Form of Age-Related Macular Degeneratio. *Hell. J Cardiol.* 54:435–440.
- Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Cancarini, A., *et al.*, (2015). Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. *Curr. Drug Metab.* 16.
- Semeraro, F., Morescalchi, F., Parmeggiani, F., Arcidiacono, B. and Costagliola, C., (2011). Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. *Curr Vasc Pharmacol.* 9(5):629–46.
- Sherwood, L., (2014). Fisiologi manusia: dari sel ke sistem. Jakarta: EGC.
- Stec, J. J., Silbershatz, H., Tofler, G. H., Matheney, T. H., Sutherland, P., *et al.*, (2000). Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population. *Circulation.* 102:1634–1638.

- Tennent, G. A., Brennan, S. O., Stangou, A. J., Grady, J. O., Hawkins, P. N., *et al.*, (2019). Human plasma fibrinogen is synthesized in the liver. *Blood*. 109(5):1971–1975.
- Ueta, T., Noda, Y., Toyama, T. and Yamaguchi, T., (2019). Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration Systematic Review and Meta-analysis of Randomized Trials. *Ophthalmology*. 121(11):2193–2203.
- Varounis, C., Katsi, V., Nihoyannopoulos, P., Lekakis, J. and Tousouli, D., (2017). Cardiovascular Hypertensive Crisis : Recent evidence and Review of the Literature. *Front. Cardiovasc. Med*. 3(51).
- Wang, W. and Zhang, X., (2014). Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration : A Meta-Analysis. *PLoS One*. 9(10):1–8.
- Wang, X. and Ohji, M., (2013). Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. *Taiwan J. Ophthalmol*. 3(4):128–133.
- Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., *et al.*, (2017). 2017 Guideline for the prevention, detection, guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *J Am Coll Cardiol*. 70(14):1785–1822.
- Yashkin, A. P., Hahn, P. and Sloan, F. A., (2016). Introduction of Anti-VEGF Therapies for Age-Related Macular Degeneration Did Not Raise Risk of Myocardial Infarction, Stroke, and Death. *Ophthalmology*. 123(10):2225–2231.
- Yi, Z., Chen, C., Su, Y., Li, L. and Zhou, Y., (2014). Changes in clotting time, plasma fibrinogen levels, and blood viscosity after administration of ranibizumab for treatment of choroidal neovascularization. *Curr Eye Res*. 40(11):1166–1171.